Comprehensive Stock Comparison
Compare C4 Therapeutics, Inc. (CCCC) vs Recursion Pharmaceuticals, Inc. (RXRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | RXRX | 26.9% revenue growth vs CCCC's -100.0% |
| Stability / Safety | CCCC | Beta 1.55 vs RXRX's 2.38 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CCCC | -0.4% vs RXRX's -51.1% |
| Efficiency (ROA) | CCCC | -29.2% ROA vs RXRX's -43.7%, ROIC -36.9% vs -95.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders — a new class of medicines that eliminate disease-causing proteins rather than just inhibiting them. It generates revenue primarily through strategic collaborations and milestone payments from partners like Roche and Biogen, with future potential from drug royalties and product sales if its pipeline succeeds. The company's key advantage is its proprietary TORPEDO platform for designing selective protein degraders, which could offer better efficacy and safety than traditional inhibitors for challenging drug targets.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an industrialized, technology-driven platform to discover and develop new drugs. It generates revenue primarily through research collaborations and partnerships with pharmaceutical companies — like its major deal with Bayer — while advancing its own pipeline of drug candidates. Its key competitive advantage is its proprietary platform that combines automation, artificial intelligence, and massive biological datasets to systematically decode biology and accelerate drug discovery at scale.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CCCC leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 2 categories are tied.
Financial Metrics (TTM)
RXRX and CCCC operate at a comparable scale, with $75M and $0 in trailing revenue. On growth, RXRX holds the edge at +6.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CCCCC4 Therapeutics, … | RXRXRecursion Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $75M |
| EBITDAEarnings before interest/tax | -$115M | -$564M |
| Net IncomeAfter-tax profit | -$105M | -$645M |
| Free Cash FlowCash after capex | -$99M | -$378M |
| Gross MarginGross profit ÷ Revenue | — | -32.1% |
| Operating MarginEBIT ÷ Revenue | — | -8.7% |
| Net MarginNet income ÷ Revenue | — | -8.6% |
| FCF MarginFCF ÷ Revenue | — | -5.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -5.8% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | +60.4% |
Valuation Metrics
| Metric | CCCCC4 Therapeutics, … | RXRXRecursion Pharmac… |
|---|---|---|
| Market CapShares × price | $262M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $247M | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -2.13x | -2.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 25.96x |
| Price / BookPrice ÷ Book value/share | 0.87x | 1.45x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CCCC delivers a -40.9% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-57 for RXRX. RXRX carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to CCCC's 0.23x. On the Piotroski fundamental quality scale (0–9), RXRX scores 4/9 vs CCCC's 3/9, reflecting mixed financial health.
| Metric | CCCCC4 Therapeutics, … | RXRXRecursion Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -40.9% | -57.0% |
| ROA (TTM)Return on assets | -29.2% | -43.7% |
| ROICReturn on invested capital | -36.9% | -95.8% |
| ROCEReturn on capital employed | -36.6% | -50.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.23x | 0.07x |
| Net DebtTotal debt minus cash | -$15M | -$665M |
| Cash & Equiv.Liquid assets | $75M | $743M |
| Total DebtShort + long-term debt | $60M | $78M |
| Interest CoverageEBIT ÷ Interest expense | — | -491.16x |
Total Returns (with DRIP)
A $10,000 investment in RXRX five years ago would be worth $2,039 today (with dividends reinvested), compared to $637 for CCCC. Over the past 12 months, CCCC leads with a -0.4% total return vs RXRX's -51.1%. The 3-year compound annual growth rate (CAGR) favors CCCC at -20.0% vs RXRX's -23.4% — a key indicator of consistent wealth creation.
| Metric | CCCCC4 Therapeutics, … | RXRXRecursion Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +39.9% | -12.6% |
| 1-Year ReturnPast 12 months | -0.4% | -51.1% |
| 3-Year ReturnCumulative with dividends | -48.8% | -55.0% |
| 5-Year ReturnCumulative with dividends | -93.6% | -79.6% |
| 10-Year ReturnCumulative with dividends | -89.4% | -79.6% |
| CAGR (3Y)Annualised 3-year return | -20.0% | -23.4% |
Risk & Volatility
CCCC is the less volatile stock with a 1.55 beta — it tends to amplify market swings less than RXRX's 2.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CCCC currently trades 74.0% from its 52-week high vs RXRX's 46.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CCCCC4 Therapeutics, … | RXRXRecursion Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 2.38x |
| 52-Week HighHighest price in past year | $3.65 | $7.89 |
| 52-Week LowLowest price in past year | $1.09 | $2.98 |
| % of 52W HighCurrent price vs 52-week peak | +74.0% | +46.5% |
| RSI (14)Momentum oscillator 0–100 | 76.0 | 46.7 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 18.2M |
Analyst Outlook
Wall Street rates CCCC as "Buy" and RXRX as "Hold". Consensus price targets imply 199.7% upside for RXRX (target: $11) vs 184.1% for CCCC (target: $8).
| Metric | CCCCC4 Therapeutics, … | RXRXRecursion Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $7.67 | $11.00 |
| # AnalystsCovering analysts | 14 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | 100 | 5.59 | -94.4% |
| Recursion Pharmaceu… (RXRX) | 183.44 | 23.22 | -87.3% |
Recursion Pharmaceu… (RXRX) returned -80% over 5 years vs C4 Therapeutics, In… (CCCC)'s -94%.
Chart 2Revenue Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | $19M | $0.00 | -100.0% |
| Recursion Pharmaceu… (RXRX) | $2M | $75M | +4264.8% |
C4 Therapeutics, Inc.'s revenue grew from $19M (2018) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | -81.1% | -3.0% | +96.4% |
| Recursion Pharmaceu… (RXRX) | -36.5% | -8.6% | +76.4% |
Chart 4EPS Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| C4 Therapeutics, In… (CCCC) | -1.06 | -1.27 | -19.8% |
| Recursion Pharmaceu… (RXRX) | -0.37 | -1.44 | -285.9% |
C4 Therapeutics, Inc.'s EPS grew from $-1.06 (2018) to $-1.27 (2025).
Chart 5Free Cash Flow — 5 Years
C4 Therapeutics, Inc. generated $-99M FCF in 2025 (-13% vs 2021). Recursion Pharmaceuticals, Inc. generated $-378M FCF in 2025 (-91% vs 2021).
CCCC vs RXRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CCCC or RXRX a better buy right now?
Analysts rate C4 Therapeutics, Inc. (CCCC) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CCCC or RXRX?
Over the past 5 years, Recursion Pharmaceuticals, Inc. (RXRX) delivered a total return of -79.6%, compared to -93.6% for C4 Therapeutics, Inc. (CCCC). A $10,000 investment in RXRX five years ago would be worth approximately $2K today (assuming dividends reinvested). Over 10 years, the gap is even starker: RXRX returned -79.6% versus CCCC's -89.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CCCC or RXRX?
By beta (market sensitivity over 5 years), C4 Therapeutics, Inc. (CCCC) is the lower-risk stock at 1.55β versus Recursion Pharmaceuticals, Inc.'s 2.38β — meaning RXRX is approximately 54% more volatile than CCCC relative to the S&P 500. On balance sheet safety, Recursion Pharmaceuticals, Inc. (RXRX) carries a lower debt/equity ratio of 7% versus 23% for C4 Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CCCC or RXRX?
C4 Therapeutics, Inc. (CCCC) is the more profitable company, earning 0.0% net margin versus -863.4% for Recursion Pharmaceuticals, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCCC leads at 0.0% versus -867.9% for RXRX. At the gross margin level — before operating expenses — RXRX leads at 5.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CCCC or RXRX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CCCC or RXRX better for a retirement portfolio?
For long-horizon retirement investors, C4 Therapeutics, Inc. (CCCC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2.38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCCC: -89.4%, RXRX: -79.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CCCC and RXRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.